PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer

Histopathology

Volumn 63, Issue 5, 2013, Pages 670-677

  Cordes, Inga ^a   Kluth, Martina ^a   Zygis, Dominika ^a   Rink, Michael ^a   Chun, Felix ^a   Eichelberg, Christian ^a   Dahlem, Roland ^a   Fisch, Margit ^a   Höppner, Wolfgang ^b   Wagner, Walter ^c   Doh, Ousman ^d   Terracciano, Luigi ^e   Simon, Ronald ^a   Wilczak, Waldemar ^a   Sauter, Guido ^a   Minner, Sarah ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Clinical Center Itzehoe   (Germany)

^c Bundeswehrkrankenhaus Hamburg   (Germany)

^d Regio Klinik Wedel   (Germany)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Bladder cancer; PTEN; Tissue microarray

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CONTROLLED STUDY; EARLY CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; SMOKING; TISSUE MICROARRAY;

BLADDER CANCER; PTEN; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; GENE DELETION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PTEN PHOSPHOHYDROLASE; URINARY BLADDER NEOPLASMS;

EID: 84885420466     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12209     Document Type: Article

References (51)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011; 61; 69-90.
2. Zhao J, Richter J, Wagner U et al. Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa). Cancer Res. 1999; 59; 4658-4661.
3. Richter J, Wagner U, Schraml P et al. Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer. Cancer Res. 1999; 59; 5687-5691.
4. Richter J, Beffa L, Wagner U et al. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am. J. Pathol. 1998; 153; 1615-1621.
5. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J. Biol. Chem. 1998; 273; 13375-13378.
6. Roymans D, Slegers H. Phosphatidylinositol 3-kinases in tumor progression. Eur. J. Biochem. 2001; 268; 487-498.
7. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 2002; 14; 381-395.
8. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 2011; 11; 289-301.
9. Ach T, Zeitler K, Schwarz-Furlan S et al. Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. Virchows Arch. 2012; 462; 65-72.
10. Yanagawa N, Leduc C, Kohler D et al. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma. J. Thorac. Oncol. 2012; 7; 1513-1521.
11. Wikman H, Lamszus K, Detels N et al. Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res. 2012; 14; R49.
12. Krohn A, Diedler T, Burkhardt L et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am. J. Pathol. 2012; 181; 401-412.
13. Mina S, Bohn BA, Simon R et al. PTEN deletion is rare but often homogeneous in gastric cancer. J. Clin. Pathol. 2012; 65; 693-698.
14. Kinross KM, Montgomery KG, Kleinschmidt M et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J. Clin. Invest. 2012; 122; 553-557.
15. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res. 1994; 54; 531-538.
16. Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene 1997; 14; 3059-3066.
17. Kagan J, Liu J, Stein JD et al. Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer. Oncogene 1998; 16; 909-913.
18. Cairns P, Evron E, Okami K et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 1998; 16; 3215-3218.
19. Aveyard JS, Skilleter A, Habuchi T, Knowles MA. Somatic mutation of PTEN in bladder carcinoma. Br. J. Cancer 1999; 80; 904-908.
20. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin. Cancer Res. 2009; 15; 6008-6017.
21. Wang DS, Rieger-Christ K, Latini JM et al. Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. Int. J. Cancer 2000; 88; 620-625.
22. Kallioniemi A, Kallioniemi OP, Citro G et al. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosom. Cancer 1995; 12; 213-219.
23. Hurst CD, Fiegler H, Carr P, Williams S, Carter NP, Knowles MA. High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene 2004; 23; 2250-2263.
24. Hurst CD, Platt FM, Taylor CF, Knowles MA. Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis. Clin. Cancer Res. 2012; 18; 5865-5877.
25. Blaveri E, Brewer JL, Roydasgupta R et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin. Cancer Res. 2005; 11; 7012-7022.
26. Lindgren D, Sjodahl G, Lauss M et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS ONE 2012; 7; e38863.
27. Liu J, Babaian DC, Liebert M, Steck PA, Kagan J. Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens. Mol. Carcinog. 2000; 29; 143-150.
28. Sjodahl G, Lauss M, Gudjonsson S et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS ONE 2011; 6; e18583.
29. Sun CH, Chang YH, Pan CC. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 2012; 58; 1054-1063.
30. Lee H, Choi SK, Ro JY. Overexpression of DJ-1 and HSP90alpha, and loss of PTEN associated with invasive urothelial carcinoma of urinary bladder: possible prognostic markers. Oncol. Lett. 2012; 3; 507-512.
31. Schultz L, Albadine R, Hicks J et al. Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer 2010; 116; 5517-5526.
32. Wild PJ, Kunz-Schughart LA, Stoehr R et al. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int. J. Oncol. 2005; 27; 385-391.
33. Bubendorf L. High-throughput microarray technologies: from genomics to clinics. Eur. Urol. 2001; 40; 231-238.
34. Mostofi F, Sobin L, Torloni H. Histological typing of urinary bladder tumors. International classification of tumors, 10th edn. Geneva: World Health Organization, 1973.
35. UICC. Classification of malignant tumors, 4th edn. Berlin: Springer, 1992.
36. Wang MR, Perissel B, Taillandier J et al. Nonrandom changes of chromosome 10 in bladder cancer. Detection by FISH to interphase nuclei. Cancer Genet. Cytogenet. 1994; 73; 8-10.
37. Deliveliotis C, Georgoulakis J, Skolarikos A et al. DNA ploidy as a prognostic factor in muscle invasive transitional cell carcinoma of the bladder. Urol. Res. 2005; 33; 39-43.
38. Cianciulli AM, Bovani R, Leonardo F et al. Interphase cytogenetics of bladder cancer progression: relationship between aneusomy, DNA ploidy pattern, histopathology, and clinical outcome. Int. J. Clin. Lab. Res. 2000; 30; 5-11.
39. Koksal IT, Yasar D, Dirice E et al. Differential PTEN protein expression profiles in superficial versus invasive bladder cancers. Urol. Int. 2005; 75; 102-106.
40. Tsuruta H, Kishimoto H, Sasaki T et al. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res. 2006; 66; 8389-8396.
41. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 2009; 23; 675-680.
42. Litlekalsoy J, Hostmark JG, Costea DE, Illemann M, Laerum OD. Time-dependent biological differences in molecular markers of high-grade urothelial cancer over 7 decades (ras proteins, pTEN, uPAR, PAI-1 and MMP-9). Virchows Arch. 2012; 461; 541-551.
43. Gonzalez-Roibon ND, Chaux A, Al-Hussain T et al. Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder. Hum. Pathol. 2012; 44; 612-622.
44. Mattocks CJ, Morris MA, Matthijs G et al. A standardized framework for the validation and verification of clinical molecular genetic tests. Eur. J. Hum. Genet. 2010; 18; 1276-1288.
45. Bartek J, Bartkova J, Vojtesek B et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6; 1699-1703.
46. Song H, Xu Y. Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways. Cell Cycle 2007; 6; 1570-1573.
47. Murphy CG, Morris PG. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs 2012; 23; 765-776.
48. Vivanco I, Mellinghoff IK. Epidermal growth factor receptor inhibitors in oncology. Curr. Opin. Oncol. 2010; 22; 573-578.
49. Neshat MS, Mellinghoff IK, Tran C et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl Acad. Sci. USA 2001; 98; 10314-10319.
50. Seront E, Rottey S, Sautois B et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann. Oncol. 2012; 23; 2663-2670.
51. Tredan O, Treilleux I, Wang Q et al. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. Target. Oncol. 2012. Doi: 10.1007/s11523-012-0242-9 [Epub ahead of print].